

A Chinese host genetic study discovered type I interferons and causality of cholesterol levels and WBC counts on COVID-19 severity

Huanhuan Zhu^{1,*}, Fang Zheng^{2,*}, Linxuan Li^{1,5,*}, Yan Jin^{3,*}, Yuxue Luo^{1,6,*}, Zhen Li^{4,*}, Jing Yu Zeng^{1,7}, Ling Tang⁴, Zilong Li¹, Ningyu Xia⁴, Panhong Liu^{1,5}, Dan Han⁴, Ying Shan¹, Xiaoying Zhu⁴, Siyang Liu^{1,8}, Rong Xie⁴, Yilin Chen⁴, Wen Liu⁴, Longqi Liu¹, Xun Xu^{1,9}, Jian Wang^{1,10}, Huanming Yang^{1,10}, Xia Shen¹¹, Xin Jin^{1,6,#}, Fanjun Cheng^{4,#}

1. BGI-Shenzhen, Shenzhen, Guangdong 518083, China.
2. Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
3. Department of Emergency medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
4. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
5. College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
6. School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, China.
7. College of Innovation and Experiment, Northwest A&F University, Yangling, Shaanxi, 712100, China.
8. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, 510006, Guangdong, China.
9. Guangdong Provincial Key Laboratory of Genome Read and Write, BGI-Shenzhen, Shenzhen, Guangdong 518120, China.
10. James D. Watson Institute of Genome Science, Hangzhou, Zhejiang 310008, China.
11. Biostatistics Group, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China

*. These authors contributed equally to this work.

#. These authors are co-corresponding authors.

Correspondence: Xin Jin (jinxin@genomics.cn) or Fanjun Cheng (chengfanjun001@sina.com)

1 **Abstract**

2 As of early May 2021, the ongoing pandemic COVID-19 has caused over 160 million of infections
3 and over 3 million deaths worldwide. Many risk factors, such as age, gender, and comorbidities,
4 have been studied to explain the variable symptoms of infected patients. However, these effects
5 may not fully account for the diversity in disease severity. Here, we present a comprehensive
6 analysis of a broad range of patients' laboratory and clinical assessments to investigate the genetic
7 contributions to COVID-19 severity. By performing GWAS analysis, we discovered several
8 concrete associations for laboratory features. Based on these findings, we performed Mendelian
9 randomization (MR) analysis to investigate the causality of laboratory traits on disease severity.
10 From the MR study, we identified two causal traits, cholesterol levels and WBC counts. The
11 functional gene related to cholesterol levels is *ApoE* and people with particular *ApoE* genotype are
12 more likely to have higher cholesterol levels, facilitating the process that SARS-CoV-2 binds on
13 its receptor ACE2 and aggravating COVID-19 disease. The functional gene related to WBC counts
14 is *MHC* system that plays a central role in the immune system. The host immune response to the
15 SARS-CoV-2 infection greatly affects the patients' severity status and clinical outcome.
16 Additionally, our gene-based and GSEA analysis revealed interferon pathways, including type I
17 interferon receptor binding, regulation of IFNA signaling, and SARS coronavirus and innate
18 immunity. We hope that our work will make a contribution in studying the genetic mechanisms of
19 disease illness and serve as useful reference for the clinical diagnosis and treatment of COVID-19.

20 **Keywords:** COVID-19, Genome-wide association study, Mendelian randomization, GSEA
21 analysis, *ApoE* gene, *MHC* system, IFNA pathway

22

23 Introduction

24 The coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute
25 respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the late December of 2019, the COVID-
26 19 has spread rapidly around the world leading to an ongoing pandemic. As of early May 2021,
27 reported to the world health organization (WHO), there have been over 160 million confirmed
28 cases of COVID-19, including over 3 million deaths. Common symptoms include fever, cough,
29 and fatigue. Meanwhile, the symptoms could be largely variable; for example, about a third of
30 patients do not develop noticeable symptoms; of patients who develop noticeable symptoms, 81%
31 develop mild to moderate symptoms, while 14% develop severe symptoms, and 5% suffer critical
32 symptoms¹. Many key factors have been reported to be associated with COVID-19 severity, such
33 as age, sex, and comorbidities. Specifically, older people are more likely to be infected by SARS-
34 CoV-2 and experience more severe symptoms. Global data indicate higher COVID-19 fatality rates
35 among men than women. Most countries reported that the male case fatality is more than 1.0 higher
36 than that of female^{2,3}. Besides, comorbidities have a critical role in poor outcomes, severity of
37 disease and high fatality rate of COVID-19 cases⁴. However, these risk factors cannot fully explain
38 the clinical variability among the patients.

39 Many recent studies turn their attention to the host genetic backgrounds and believe that
40 the genetic factor may play an essential role in determining the host responses to SARS-CoV-2⁵⁻
41 ⁹. By performing large-scale genome-wide association studies (GWAS) of COVID-19 clinical
42 phenotypes, several disease-associated variants and genes were identified and summarized by the
43 Host Genetics Initiative (HGI)⁹, such as the rs11385942 (*SLC6A20*), rs657152 (*ABO*), and
44 rs2236757 (*IFNAR2*)^{10,11}. Among these findings, *SLC6A20* encodes a proline transporter and is
45 functionally associated with *ACE2* (angiotensin-converting enzyme 2), which encodes the well-
46 known SARS-CoV-2 receptor¹⁰; gene *IFNAR2* encodes one type of I interferons that is essential
47 to the establishment of antiviral state and intensifying to antiviral response¹². However, most of
48 existing GWAS studies are based on the European populations, or meta-analysis with multiple
49 populations. It is a pity that the genomic studies based on Asian populations, especially Chinese
50 population, are relatively few. Wang et al. (2020) reported the first host genetic study in the Chinese
51 population of 332 COVID-19 patients and suggested some relatively significant genetic loci as
52 candidate variants associated with severity status⁵. However, their study did not identify any

53 genome-wide significant genetic variants (p-values < 5E-08) due to a small sample size and limited
54 effects of single variants.

55 In our study, we performed extensive GWAS analyses for a wide range of laboratory
56 assessments measured from the blood test of 466 COVID-19 patients. Even with a relatively small
57 sample size, our GWAS results indeed identified several concrete genome-wide significant
58 associations, which are either the first replication study for a previously reported signal or the first
59 discovery in Chinese population based on genetic analysis. These variant-trait associations include
60 rs1801020 (*F12*) with activated partial thromboplastin time, rs56393506 (*LPA*) with lipoprotein-
61 A, rs28946889 (*UGT1A* complex) with total/indirect bilirubin levels, rs7412 (*ApoE*) with low-
62 density lipoprotein cholesterol levels (LDL-C), and rs9268517 (*BTNL2*) with white blood cell
63 counts (WBC). Based on these substantial findings, we implemented Mendelian randomization
64 (MR) to examine whether these traits are causal factors to the COVID-19 susceptibility and
65 severity.

66 MR uses genetic variants as instrumental variables to determine whether an observational
67 association between a risk exposure and an outcome disease is also a causality¹³. In recent years,
68 MR has rapidly gained popularity in epidemiology and medical research, because of the ever-
69 expanding genetic databases and well-powered GWAS studies on a large number of traits. We
70 selected the above traits with established associations as exposure variables and the COVID-19
71 severity status released by the HGI database as the outcome variable. By performing MR analysis,
72 we uncovered the causal associations of LDL-C and WBC on the disease severity. The cholesterol
73 level and WBC counts-related genes are *ApoE* and *MHC* (major histocompatibility complex)
74 system, respectively. We further studied the genetic architecture of how *ApoE* affects the severe
75 illness of COVID-19 and revealed that *ApoE* could affect the severity of COVID-19 by influencing
76 cholesterol levels in the peripheral tissues. Specifically, people with particular *ApoE* genotype are
77 more likely to have higher levels of cholesterol, which leads the plasma membrane to form more
78 lipid rafts. Compared to other people, these people are more vulnerable to SARS-CoV-2 as more
79 lipid rafts would facilitate the binding of the virus to its target receptor ACE2¹⁴. The genetic
80 mechanisms of how *MHC* system contributes to the susceptibility and severity of COVID-19 are
81 mainly through activating and regulating the immune system. Specifically, MHC family works as
82 an immune activator and directly triggers the proliferation of lymphocyte cells. As the number of
83 lymphocyte cell increases, immune system springs into action against SARS-CoV-2. Therefore,

84 the abnormal change of immune cell counts and the MHC expression levels often used as
85 indicators of the severity of COVID-19 symptom ¹⁵.

86 We further performed gene-based studies and gene-set enrichment analysis (GSEA) based
87 on the GWAS single-variant associations for testing COVID-19 severity. As a result, we
88 successfully discovered four functional pathways: regulation of IFNA signaling, SARS
89 coronavirus and innate immunity, type I interferon receptor binding, and overview of interferons-
90 mediated signaling pathway. The type I interferon (IFN-I) can bind to the receptor on the surface
91 of immune cell membrane, mobilize and enhance the activity of immune cells, prevent the
92 transmission of virus between cells, and clear the cells infected by the virus ^{16,17}. A study reported
93 that the characteristic of severe COVID-19 cases was the IFN-I response and the mouse model of
94 SARS-CoV-2 infection showed that the timing of IFN-I response is the key factor to determine the
95 outcome of infection ¹⁸. In March 2020, the National Health Commission and the National
96 Administration of Traditional Chinese Medicine issued the COVID-19 diagnosis and treatment
97 plan, IFN-I is one of the main antiviral drugs ¹⁹. To the best of our knowledge, this is the first time
98 that the interferons-related pathways are uncovered from the genetic studies of COVID-19 patients
99 in Chinese population.

100 In summary, we succeeded in identifying genome-wide significant associations between
101 genetic variants and laboratory traits measured from Chinese ancestry COVID-19 patients. Most
102 of these findings were supported by previous literatures. On the basis of these concrete associations,
103 we conducted MR analysis and detected two candidate genes, *ApoE* and *MHC* system, which
104 influence the severity status by acting on cholesterol levels and WBC counts, respectively. Besides,
105 we identified four interferons functional pathways that directly determine the COVID-19 disease
106 severity based on genomic studies of infected patients. These findings provide new insights in
107 studying the genetic mechanisms of COVID-19 susceptibility and severity. We hope that our work
108 will serve as useful reference for academic field and make contribution to investigate the COVID-
109 19 disease and finally stop the pandemic.

110

111 Results

112 **Basic information of the enrolled patients.** After quality control (Materials and Methods), there
113 were 466 patients used for analysis, of which 229 were males (49.1%) and 237 were females
114 (50.9%) (Figure 1A). The age of patients ranged from 23 to 97, composing with 20-39 (8.5%), 40-
115 59 (31.1%), 60-79 (51.1%), and 80-99 (9.2%) (Figure 1A). According to the patients' severity of
116 illness at the time of admission to the hospital, they were classified into four categories as mild (N
117 = 6, 1.29%), moderate (N = 164, 35.19%), severe (N = 227, 48.71%), and critical (N = 69, 14.81%).
118 The method of classifying severity followed the criteria made by the National Health Commission
119 of the People's Republic of China²⁰. We further broadly defined the mild group as mild and
120 moderate patients (N = 170) and the severe group as severe and critical patients (N = 296) (Figures
121 1B-1C). We then fitted a single factor linear regression model and statistically proved that age was
122 a risk factor for severe symptoms of COVID-19 (z-score = 4.146, p-value = 3.38E-05). Besides,
123 we performed a Fisher's exact test to test the independence of patients' gender and severity and
124 found a significant correlation (OR = 1.59, p value = 0.016), revealing a higher propensity for
125 severe in males with COVID-19. These phenomena were consistent with reports from previous
126 literatures^{21,22}.

127 More than 50% of the patients (N = 288) had at least one comorbidity prior to admission
128 to the hospital, and the most frequent ones were hypertension (N = 180, 38.63%), diabetes (N =
129 95, 20.38%), and coronary heart disease (N = 63, 13.52%). The distribution of comorbidities
130 among mild and severe patients is provided in Figure 1D. We then tested whether the presence or
131 absence of comorbidities would affect the patients' severity by performing a Fisher's exact test
132 and found that having comorbidities is a risk determinant to develop severe symptoms (OR = 1.86,
133 p = 2.09E-03). This conclusion has been supported by many studies^{23,24}. Most of the patients
134 experienced various COVID-19 symptoms, including cough (N = 302, 64.81%), fatigue (N = 200,
135 42.92%), and chest tightness (N = 188, 40.34%). We also reported the distribution of symptoms
136 among mild and severe patients (Figure 1D).

137 **Genome-wide association analysis of laboratory features.** We first evaluated the imputation
138 accuracy of genetic variants by two measurements: imputation score and correlation with chip
139 array sequencing. After quality control (Materials and Methods), a total of 6,349,370 variants were

140 selected for further analysis and 99.6% of these variants had imputation score over 0.8 based on
141 reference panel as EAS population from the 1000 Genome Project. In addition, 214 patients were
142 sequenced with high depth and high coverage. We took overlap of variants between their chip
143 array genotypes and imputed genotypes and it yield 479,823 sites. Over 98.1% patients had
144 correlation coefficients above 0.8 across these genetic sites. With a mean sequencing depth of
145 17.8x, we finally tested a total of 6,185,321 autosomal variants and 164,049 X-chromosome
146 variants for association with 78 quantitative laboratory traits in 466 COVID-19 patients. These
147 laboratory measurements were grouped into 10 distinct categories ([Table 1](#)): hematological (n =
148 22), anticoagulation (n = 7), electrolyte (n = 7), lipid (n = 7), protein (n = 4), liver-related (n = 12),
149 kidney-related (n = 3), heart-related (n = 8), inflammation (n = 3), and other biochemical (n = 5).
150 The study workflow is designed as in [Figure 2](#). When we applied multiple-testing correction to the
151 number of the studied traits, 5 variant-trait associations were significant signals (p-value < 5E-
152 08/78 = 6.41E-10), 4 out of which were previously identified in either European, Asian, or both
153 populations ([Table 2](#)). These associations include rs1801020 (*F12*, p-value = 4.13E-16) with
154 activated partial thromboplastin time (APTT), rs56393506 (*LPA*, p-value = 1.97E-14) with
155 lipoprotein-A (LpA), rs28946889 (*UGT1A* complex, p-value = 5.08E-14) with total bilirubin
156 levels (Tbil), and rs28946889 (*UGT1A* complex, p-value = 1.51E-16) with indirect bilirubin levels
157 (Ibil). The Manhattan plots and QQ-plots were drawn for APTT, LpA, and Ibil with the CMplot
158 package in R ²⁵ and provided in [Figure 3](#). A novel association was rs11032789 (*EHF*, p-value =
159 6.40E-10) with apoprotein A (apoA). Even though the association between rs7412 (*ApoE*, pvalue
160 = 2.30E-08) and low-density lipoprotein cholesterol levels (LDL-C) did not reach the study-wide
161 significance threshold, it had been widely identified in European, Asian, and Chinese populations.
162 The association between rs9268517 (*BTNL2*, p-value = 4.05E-08) with white blood cell counts
163 (WBC) did not pass the threshold either. Considering that *BTNL2* encodes a major
164 histocompatibility complex (MHC) class II protein and is involved in immune surveillance, we
165 considered this identified association was a worth-investigating signal. The Manhattan plots for
166 LDL-C and WBC were provided in [Figure 4A](#) and [Figure 5A](#), respectively.

167 We additionally illustrated more details on the above detected associations. Specifically,
168 the rs1801020 (*F12*)-APTT association was previously identified in GWAS analysis from the
169 BioBank Japan Project (BBJ), one of the largest East Asian biobanks with over 160,000 subjects

170 ²⁶. The gene *F12* encodes coagulation factor XII that participates in the initiation of blood
171 coagulation and mutation of *F12* will cause prolonged coagulation time and poor thromboplastin
172 production ²⁷. The rs56393506 (*LPA*)-LpA association was previously identified by GWAS in
173 European population with over 13,781 individuals ²⁸ but not in Asian population based on genomic
174 studies. The gene *LPA* encodes a serine proteinase that constitutes a substantial portion of
175 lipoprotein(a) ²⁹. The rs28946889 (*UGT1A* complex)-Tbil and *UGT1A* complex-Ibil associations
176 were identified from the BBJ database ²⁶. The *UGT1A* complex represents a complex locus that
177 encodes several UDP-glucuronosyltransferases. The mutation of *UGT1A1* gene is the only enzyme
178 involved in bilirubin glucuronidation in hepatocytes, which can reduce the activity of the enzyme
179 and cause insufficient bilirubin glucuronidation, thus increasing the level of serum bilirubin. The
180 rs7412 (*ApoE*)-LDL-C association was previously identified by GWAS analysis in European,
181 Asian, and Chinese populations. The gene *ApoE* is a type of apolipoprotein that participates in
182 lipid metabolism and particular *ApoE* genotype results in higher risk of elevated LDL-C levels.
183 The rs9268517-WBC is a novel genetic association identified by our GWAS analysis. However,
184 its closest gene *BTNL2* was previously identified to be associated with WBC by a GWAS analysis
185 with 408,112 European individuals ³⁰. The gene *BTNL2* encodes MHC II type I transmembrane
186 protein and binding to its receptor can inhibit T cell activation and cytokine production.

187 **Two-sample Mendelian randomization analysis.** Yet we have the individual-level genotypic
188 data, laboratory measurements, and clinical severity to perform one-sample MR analysis, we
189 choose not to do so due to the small sample size and low powers and also its less powerful
190 performance in controlling for confounders. We instead examined the causal relationships between
191 the laboratory measurements with concrete genome-wide associations and COVID-19
192 susceptibility and severity tested by various phenotype types from the Host Genetics Initiative
193 (HGI) database based on the two-sample MR analysis. Typically, the two-sample MR study
194 requires two independent studies from one population to ensure consistent SNP sites. We
195 harmonized the summary results from exposure and outcome studies to adjust the SNP sites into
196 positive chains and remove inconsistent ones with large allele frequency difference
197 (Supplementary [Table S1](#)). In brief, we identified three leniently significant causal associations (p-
198 value < 0.05), including WBC counts (p-value = 0.009), LDL-C (p-value = 0.034), and apoA (p-
199 value = 0.047) on the susceptibility and severity of COVID-19 disease. The valid instrumental
200 variants used for LDL-C, apoA, and WBC are rs7412 (*ApoE*), rs11032789 (*EHF*), and rs9268517

201 (*BTNL2*), respectively. After SNPs clumping and pruning, there was only one SNP used in MR
202 analysis for each trait and therefore the Wald ratio method³¹ was used to estimate the causal effects.
203 Typically, the minimum number of independent SNPs is three²⁶ and the inverse variance weighted
204 method³² is often used to estimate the causal effects. Furthermore, by controlling the false
205 discovery rate (FDR), the q-values are all greater than 0.05 for the above identified associations
206 with 84 multiple testing (7 laboratory traits * 12 HGI phenotypes). Despite the small number of
207 valid instrumental variants applied in the analysis and insignificant results with large multiple
208 testing burden, our results still provide worthwhile directions for further investigation. We detected
209 these valuable genetic mechanisms of COVID-19 disease: *ApoE* and *MHC* family influence the
210 COVID-19 susceptibility and severity status by acting on the cholesterol levels and WBC counts
211 of patients, respectively.

212 We adopted other large-scale publicly available databases and evaluated whether our
213 findings were also suggested by these databases. To investigate the causal effects of LDL-C, we
214 downloaded the significant summary statistics for LDL-C from the BBJ database with sample size
215 72,866²⁶. There are 22 genome-wide associated variants mapped to different genes. First, we
216 tested on only the *ApoE* gene by using SNPs mapped to this gene (rs769446, p-value = 2.977E-
217 322, LD with rs7412 = 0.56 in 1000 Genome Project all populations). Hereby, there was one valid
218 instrumental SNP, and the Wald ratio test was used in MR analysis. The results were provided in
219 Supplementary [Table S2](#) and showed four significant associations corresponding to four HGI
220 phenotypes. The q-values (FDR) of these associations are also less than 0.1 with two less than 0.05.
221 Second, we did the MR analysis based on all the LDL-C associated 22 SNPs. After SNP clumping
222 and harmonization with HGI database, 11 SNPs were used in MR. The estimate of the causal effect
223 sizes, p-values, and q-values for testing the effect of LDL-C on susceptibility of COVID-19 were
224 provided in Supplementary [Table S3](#) and [Figures 4B-4C](#). We also used MR-Egger method³³ to
225 test the heterogeneity and the p-value is 0.464 > 0.05 (Q-statistic = 8.71) showing no heterogeneity.
226 Besides the heterogeneity, we also tested pleiotropic effects based on MR-PRESSO global test³⁴
227 and obtained a p-value of 0.228 > 0.05 meaning no direct effects of the analyzed SNPs on outcome
228 severity. The results of no heterogeneity and no pleiotropy enhanced the validity of MR results.
229 We also tested the causality of cholesterol levels on COVID-19 susceptibility and severity in
230 European population³⁵ and African American population³⁶, respectively. The results were
231 provided in Supplementary [Tables S4](#) and [S5](#) showing a possible causal effect of LDL-C on

232 COVID-19 disease in other populations besides East Asian. We mention that the causal effect
233 directions of LDL-C on disease illness varied upon analyzed SNP(s) and HGI phenotypes; showing
234 the complex biological mechanisms of how the genetic variation regulates the disease status by
235 controlling cholesterol levels.

236 Our analysis results and observations of trait measurements over time are consistent with
237 two main points of view. The first one is that people with *ApoE* $\epsilon 4/\epsilon 4$ genotype tend to have higher
238 plasma cholesterol levels compared to those with the other *ApoE* genotypes^{37,38}. Recently, several
239 studies reported that patients who carried *ApoE* $\epsilon 4/\epsilon 4$ genotype tend to be infected by SARS-CoV-
240 2 and experience severe symptoms from COVID-19^{39,40}. For example, a study concluded that,
241 among older people, patients with *ApoE* $\epsilon 4/\epsilon 4$ genotype had much higher risk of developing severe
242 symptoms compared with *ApoE* $\epsilon 3/\epsilon 3$ (OR = 2.31, p-value = 1.19E-06)³⁹. By investigating the
243 *ApoE* genotypes in all 466 COVID-19 patients, we found 7 patients who carried *ApoE* $\epsilon 4/\epsilon 4$ in
244 total, of which 5 patients were severe. We investigated the biological mechanisms of how *ApoE*
245 gene regulated the COVID-19 susceptibility and severity and found a pathway where *ApoE*
246 influenced disease status by controlling for cholesterol levels, which were consistent with our MR
247 findings. Specifically, people with *ApoE* $\epsilon 4/\epsilon 4$ have increased risk of high cholesterol levels. When
248 they are exposed to SARS-CoV-2, the accumulation of cholesterol in alveolar epithelial cells
249 increased the density of lipid rafts, from which the virus binds to its target receptor ACE2.
250 Therefore, higher density of lipid rafts facilitates the bindings in cell membranes and eventually
251 raised the susceptibility to SARS-CoV-2 infection and severity of COVID-19^{14,40,41}. The genetic
252 mechanism is illustrated in [Figure 4D](#). The second point of view is that as the disease condition
253 worsened, the lipid levels including apoA and LDL-C largely decreased⁴². Our results in the next
254 section of “Time-series analysis of laboratory features” supported this association, showing a very
255 low level of cholesterol in blood is a risk sign for suffering severe symptoms in COVID-19 cases.

256 We further tested on the *MHC* system genes. The SNPs (rs114398276) mapped to *MHC*
257 genes in BBJ database were removed when harmonizing with HGI results due to large difference
258 in allele frequency. As an alternative, we downloaded another summary result based on East Asian
259 population with sample size 151,807⁴³. First, we tested the causality of WBC counts on COVID-
260 19 severity based on SNPs mapped to *MHC* family, which is gene *HLA-C* (rs2524084, p-value =
261 1.260E-53, LD with rs9268517 = 0.21 in 1000 Genome Project all populations). The results were

262 provided in Supplementary [Table S6](#) and showed four significant associations corresponding to
263 four HGI phenotypes. The q-values (FDR) of these four associations are also less than 0.05
264 suggesting the candidate pathway that *MHC* family has an effect on COVID-19 disease by
265 controlling WBC counts. Second, we did the MR analysis based on all associated 81 SNPs. After
266 SNPs clumping and harmonization with HGI database, 48 SNPs were used in MR. The estimates
267 of the effect size, p-values, and q-values for testing the causal effects of WBC counts on disease
268 illness were provided in Supplementary [Table S7](#) and [Figures 5B-5C](#). We also used MR-Egger
269 method to test the heterogeneity and the p-value is $0.365 > 0.05$ (Q-statistic = 48.69) showing no
270 heterogeneity. Besides the heterogeneity, we also tested pleiotropic effects and obtained a p-value
271 of $0.469 > 0.05$ meaning no pleiotropy. The causal effect direction of WBC counts on COVID-19
272 illness is consistently positive based on our dataset and the tested Asian database, suggesting that
273 WBC count is likely a risk predictor to disease status.

274 We searched the gene-trait “major histocompatibility complex” + COVID-19 on PubMed
275 and it yielded 57 hits (as of May 10, 2021), indicating the essential role of the *MHC* system in the
276 immune responses of COVID-19 patients. The MHC complex is a group of related proteins that
277 are encoded by the *MHC* gene complex in human. The function of these cell-surface proteins is to
278 activate T lymphocyte cells and NK (natural killer) cells by presenting antigens. The SARS-CoV-
279 2 was found to restrain antigen presentation and suppress immune reaction by downregulating the
280 expression of *MHC* class in COVID-19 cases⁴⁴. Previous studies showed that, as the disease
281 progresses, mHLA-DR levels and lymphocyte cell counts varied in COVID-19 patients^{15,45}. In
282 conclusion, the *MHC* gene complex and its expression levels are closely related to COVID-19
283 severity of infection symptoms. The genetic mechanism is illustrated in [Figure 5D](#).

284 **Reverse Mendelian randomization analysis.** Our MR analysis in previous section suggested the
285 causal effects of LDL-C and WBC counts on COVID-19 disease. To further investigate whether
286 there exist causal effects of COVID-19 severity on LDL-C or WBC counts, we did the reverse MR
287 analysis where the illness status was exposure, and the laboratory assessments were outcome
288 variables. Specifically, we used the various HGI phenotypes⁹ as exposure and LDL-C levels and
289 WBC counts as outcome. The results were provided in Supplementary [Tables S8](#) and [S9](#) implying
290 no causality.

291 **Time-series analysis of laboratory features.** We used line chart to visualize the variation patterns
292 of laboratory measurements at five time points. Based on the severity status at admission and
293 clinical outcome in the end, the patients were grouped into three teams: mild and recovered (mild),
294 severe and recovered (recovery), and severe and dead (death). We provided the line charts for
295 apoA, LDL-C, and WBC in [Figures 6A-6C](#) and for the other traits in Supplementary Figures.
296 These line charts could visually reflect whether a trait was protective or risk to COVID-19 disease.
297 For example, the apoA and LDL-C levels were likely to be protective factors since patients in the
298 recovery and death groups had lower values than those in mild group, while the WBC counts
299 appeared to be risk predictor to COVID-19. We also performed logistic regression analysis to
300 statistically assessed the risk and protective factors to disease severity and clinical outcome
301 ([Figures 6D-6F](#)). For apoA and LDL-C, negative effects implied protective influence on disease
302 illness; while for WBC counts, the effect direction is positive indicating risk impact. We also
303 noticed that with the progress of the disease, the negative association between the lipid traits and
304 clinical outcome became more significant. Considering that patients in mild and recovery groups
305 were cured and out of hospital, these time-series analyses also could reflect the comparison of
306 laboratory features between COVID-19 cases and healthy controls.

307 **Gene-based and gene-set enrichment analysis of clinical measurements.** We analyzed three
308 clinical features, including severity (mild versus severe), clinical outcome assessments (survival
309 versus death), and disease duration (hospitalized days) by first performing single-variant genome-
310 wide association studies. The Circular-Manhattan plot and QQ-plot were provided in [Figures 7A-](#)
311 [7B](#). No genetic variants reach the genome-wide significance threshold (p -value $< 5E-08$) due to
312 the current small sample size ($N = 466$) and thus the effect sizes of single variants tend to be small.
313 To aggregate the single-variant effects, we further performed VEGAS gene-based test ⁴⁶ and
314 g:GOST GSEA analysis ⁴⁷ for clinical severity. With a window size of 50kb, 25,345 genes were
315 mapped and the average number of SNPs on each gene is 251. For the window of 10kb, 24,640
316 genes were mapped, and the average number of SNPs is 119. Then, we selected only genes with
317 p -value less than 0.05. A number of 1,170 genes passed the significance threshold for window size
318 50kb and 1099 genes for 10kb. We obtained an intersect of 705 genes from the two sets of
319 significant genes for further GSEA analysis.

320 The GSEA results identified four significant pathways with p -value less than 0.05 ([Figure](#)
321 [7C](#)). These pathways include regulation of IFNA signaling (REAC:R-HSA-912694, p -value =

322 6.42E-04), SARS coronavirus and innate immunity (WP:WP4912, p-value = 2.54E-03), overview
323 of interferons-mediated signaling pathways (WP:WP4558, p-value = 8.64E-03), and type I
324 interferon receptor binding (GO:0005132, p-value = 4.38E-02). All the four pathways belong to
325 the IFNA family, which is a member of the alpha interferon gene cluster on and encodes type I
326 interferon (IFN) family produced in response to viral infection. The IFNA family is a key part of
327 the innate immune response with potent antiviral, antiproliferative and immunomodulatory
328 properties. Insufficient virus-induced type I IFN production is characteristic of SARS-CoV-2
329 infection since SARS-CoV-2 suppresses the IFN response by interacting with essential IFN
330 signaling pathways⁴⁸. Blunted amounts of IFNs have been detected in the peripheral blood or
331 lungs of severe COVID-19 patients⁴⁹. We note that since VEGAS is based on a simulation
332 procedure to calculate the gene-based p-values, thus its results may vary slightly every time we
333 rerun the analysis. We examined the effect of running the analysis multiple times and found that
334 the results of gene-based association and the subsequent GSEA study are robust and reliable. We
335 also investigated the effect of varying the window sizes around each gene and found that the results
336 are robust to the choice of window sizes. In summary, based on the single variant associations,
337 VEGAS gene-based tests, and GSEA analysis, we identified four IFNs pathways whose
338 imbalanced responses may cause the pathology of COVID-19 based on genomic studies in Chinese
339 population.

340 As we mentioned in the Introduction section, several genetic loci have been identified to
341 be associated with the critical illness in COVID-19⁷. We summarized eight genome-wide
342 significant associations in [Table 3](#), including the lead SNP in each locus, the p-values of these
343 SNPs for testing severity status in our dataset, and their allele frequencies in Asian and European
344 populations from 1000 Genome Project and in our case subjects. Among these eight SNPs, one
345 SNP (rs74956615, 19:10427721) does not exist in our imputed genotype and two SNPs
346 (rs73064425, 3:45901089; rs3131294, 6:32180146) were removed from analysis due to low allele
347 frequencies. For four out of the other five SNPs, their allele frequencies in European populations
348 are much higher than in Asian population (average difference is 0.16), showing that these
349 significant SNPs are more prominent in European than in Asian. The eighth SNP is rs9380142
350 (6:29798794) mapped to gene *HLA-G*. The *HLA-G* gene belongs to the MHC region that plays a
351 critical role in immune responses and regulations. We believe that a large-scale COVID-19 case-
352 control study in Chinese population also has potential to uncover the MHC region.

353 **Materials and methods**

354 **Subjects.** All the subjects enrolled in this study were recruited by the Wuhan Union Hospital
355 (Union hospital of Tongji Medical College of Huazhong University of Science and Technology).
356 These subjects had been diagnosed with COVID-19 respiratory disease and hospitalized in Wuhan
357 Union Hospital between January 15 and April 4, 2020. Written informed consent was obtained
358 from all participants, as approved by the Medical Ethics Committee of Union Hospital, Tongji
359 Medical College, Huazhong University of Science and Technology.

360 **Phenotype.** There are two types of phenotypes: laboratory and clinical measurements. Numerous
361 laboratory features from various lab test categories were measured at different time points during
362 hospitalization. For each laboratory measurement, we took average of all non-missing records of
363 each patient during his or her hospitalization for genomic analysis. The clinical characteristics
364 include three traits: severity status (mild versus severe) collected at the time of admission to the
365 hospital, clinical outcome assessments (survival versus death), and disease duration (i.e.,
366 hospitalized days) at the time of eventual treatment and prevention of disease.

367 **Genotyping and imputation.** We sequenced samples with the DNBSEQ platform (MGI,
368 Shenzhen, China) to generate 100bp paired-end reads. The mean sequencing depth was 17.8×. We
369 excluded samples with (i) sample call rate < 0.99, (ii) closely related individuals identified by
370 identity-by-descent ($IBD > 0.1$) calculated in KING⁵⁰, and (iii) outliers identified by principal
371 component analysis based on three-sigma rules. We then applied standard quality control criteria
372 for genetic variants by removing those with (i) SNP call rate < 0.99, (ii) minor allele frequency
373 (MAF) < 0.01, and (iii) Hardy-Weinberg equilibrium p-value < 1E-06. Based on the VCF files
374 after VQSR with biallelic variants, imputation was performed with Beagle v4.0⁵¹ taking GL as
375 input in east Asian (EAS) population of 1000 Genomes Project as reference panel.

376 **Genome-wide association studies.** We used PLINK v2.0⁵² to perform single-variant GWAS
377 analyses using a linear regression model for the quantitative laboratory features under the
378 assumption of additive allelic effects of the SNP dosage. For each trait, we adjusted for age, sex,
379 and top six principal components (PCs) of genetic ancestry and normalized the resulting residuals
380 by applying a Z-score normal transformation. The number of PCs was chosen by using
381 EIGENSTRAT software^{53,54}. We set a genome-wide significance threshold at the level of 5E-08

382 and a study-wide significance threshold at the level of $6.41E-10$ ($=5E-08/78$) by applying
383 Bonferroni correction based on the number of laboratory traits ($n = 78$).

384 **Two-sample Mendelian randomization.** Several significant associations were identified from
385 the GWAS analysis of laboratory measurements. Given the potential genetic correlation between
386 these features and the COVID-19 susceptibility and severity, we performed two-sample Mendelian
387 randomization analyses to examine causal effects between them and uncover genetic variants that
388 determined disease status by acting on the laboratory traits. Note that the causal interpretation of
389 the laboratory exposure variable on the disease outcome requires three standard assumptions to
390 hold: (i) relevance: instrumental variants are highly associated with the exposure; (ii) no
391 unmeasured confounders: variants are not associated with any confounding factors that may be
392 associated with both exposure and outcome; and (iii) exclusion restriction: variants influence the
393 outcome only through the path of exposure, i.e., no horizontal pleiotropic effects of variants on the
394 outcome. We used the laboratory features that displayed strong study-wide signals with genetic
395 variants ($p\text{-value} < 6.41E-10$) as the variant-exposure associations to ensure the relevance
396 assumption. For the variant-outcome associations, we used the COVID-19 Host Genetics Initiative
397 (HGI) round 5 GWAS meta-analysis results and genome-wide significant variants were removed
398 to ensure the exclusion restriction assumption. There are four types of phenotypes in HGI: very
399 severe respiratory confirmed covid versus population (A2), hospitalized covid versus not
400 hospitalized covid (B1), hospitalized covid versus population (B2), and covid versus population
401 (C2). We selected B2, C2, and B1 phenotypes to study the susceptibility and critical illness of
402 COVID-19. For each type of phenotype, there are four different sets of populations: all populations
403 but not 23andme, all populations but not UKBB, all Europeans, and all Europeans but not UKBB.
404 We used R (version 4.0.2) with the *TwoSampleMR* package^{55,56} and set the significance threshold
405 at the level of 0.05. We also calculated the *adjusted* p-values (i.e., q-values) by controlling the
406 false discovery rate (FDR). In details, we used R (version 4.0.2) with the *p.adjust* function from
407 *stats* package⁵⁷ to obtain the q-values and declared more stringently significant associations based
408 on an FDR of 0.1 and 0.05.

409 **Time-series laboratory features.** To better understand the variation trends of laboratory features
410 during the patients' hospital stay, we divided the hospitalization days into several stages for each
411 patient. For each laboratory feature, we only kept patients with more than two non-missing records

412 and divided these records into two equal-length groups named early and late time stage. At each
413 of the two-time stages, we took average of all available values for each feature and treated this
414 average as the patient's representative measurement at this time stage. We also defined the first
415 and last non-missing measurement as initial and end record. In addition, we took average of all
416 non-missing records for each patient during his or her hospitalization days and used this value as
417 the overall average. By doing so, for each patient, we obtained five values of all laboratory features:
418 initial, early, average, late, and end. To test the association between the time-series laboratory traits
419 with disease severity and clinical outcome, we further performed logistic regression analysis after
420 adjusting for age and sex at each time stage.

421 **Gene-based and gene-set enrichment analysis.** For the patients' clinical features, we performed
422 GWAS single-variant analysis in PLINK 2.0 based on a logistic (for severity status and clinical
423 outcome assessments) or linear (disease duration) regression model. For the severity status, we
424 further conducted gene-based tests and gene-set enrichment analysis (GSEA) to aggregate effects
425 of multiple genetic variants from the single tests. The gene-based test is VEGAS method ⁴⁶ that
426 combines the p-values of the single variants. A list of selected genes from the gene-based results
427 was taken for further GSEA analysis to uncover functional pathways based on the g:GOST toolset
428 ⁴⁷. We used six existing gene set databases, including GO (gene ontology) molecular function ⁵⁸,
429 GO cellular component ⁵⁸, GO biological process ⁵⁸, KEGG (Kyoto encyclopedia of genes and
430 genomes) ⁵⁹, Reactome ⁶⁰, and WikiPathways ⁶¹.

431 **Data availability.** The data that support the findings of this study have been deposited into CNGB
432 Sequence Archive (CNSA) ⁶² of China National GeneBank DataBase (CNGBdb) ⁶³ with accession
433 number CNP0001876.

434

435 Discussion

436 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus
437 causing the ongoing pandemic coronavirus disease 2019 (COVID-19). Patients' with COVID-19
438 experience largely various clinical and laboratory assessments, from no symptoms, to exhausted
439 respiratory system, and even death. Many clinical and experimental studies have concluded that
440 several key determinants are responsible for the disease variability, including old age, male gender,
441 and having comorbidities at the admission to the hospital. However, these factors still cannot fully
442 account for the diverse symptoms among patients. Recent studies have turned more attentions into
443 the host genetic background. The Host Genetics Initiative (HGI) have reported many candidate
444 loci by performing large-scale GWAS analysis with thousands of cases and up to millions of
445 controls.

446 In this study, we analyzed 466 COVID-19 patients hospitalized in the Wuhan Union
447 Hospital. A broad range of clinical information, such as age, gender, comorbidities, and laboratory
448 blood test results, such as hematological and liver-related assessments were collected for each
449 patient. The analyses of age, gender, and comorbidities in mild and severe patients confirmed their
450 potential risk on critical symptoms. We also performed GWAS analysis for the numerous
451 laboratory features and discovered seven concrete genome-wide variant-trait associations, five of
452 which were previously uncovered by large-scale genomic studies. Our results were either the first
453 replication or the first identification study in Chinese population based on GWAS study. With
454 these well-established genetic associations, we conducted Mendelian randomization (MR) analysis
455 to uncover important laboratory traits that have causal effects on the susceptibility and severity of
456 COVID-19 disease. Our analyses highlighted two fundamental pathways; one is the cholesterol
457 levels with functional gene *ApoE*, and the other one is the white blood cell counts (WBC) with
458 functional gene *MHC* complex. We further researched on and well explained the genetic
459 mechanisms of how genes *ApoE* and *MHC* family influenced the disease status by acting on
460 cholesterol levels and WBC counts.

461 We additionally carried out the gene-based tests and gene-set enrichment analysis (GSEA)
462 based on the single-variant GWAS summary results of severity case-control study. Interestingly,
463 we for the first time revealed four interferons (IFNs) related functional pathways based on host
464 genetic studies in Chinese population, including regulation of IFNA signaling, SARS coronavirus

465 and innate immunity, overview of interferons-mediated signaling pathway, and type I interferon
466 receptor binding. Several considerable studies observed that low levels of IFNs production was
467 highly correlated with severe COVID-19. Most of these studies were based on bulk RNA-seq,
468 scRNA-seq, or experimental designs, while our analysis is built on genomic data, supporting this
469 solid conclusion from a new perspective.

470 Despite the many compelling discoveries of our work, there are still a few limitations. First,
471 the single-variant GWAS analysis of severity status did not identify any genome-wide signals due
472 to the current sample size ($N = 466$) and thus small genetic effect sizes. We believe that large-scale
473 case-control studies have potentials to uncover genome-wide significant variants. Second, even
474 though our GWAS analysis of laboratory features produced concrete and powerful signals, there
475 are still many more traits without being detected associated variants that reach the study-wide or
476 the genome-wide significance threshold. For the identified associations, after SNPs clumping and
477 pruning, there is merely one independent strong variant, while the tested traits were often known
478 as polygenic. This is still due to small sample size restriction. Third, despite the fact that our MR
479 findings are supported by solid biological mechanisms and also potentially replicated by many
480 populations, the causal significance could be different among different HGI phenotypes. For
481 example, when testing the causal effects of LDL-C based on BBJ database, with the outcome of
482 covid vs. population in all population without UKBB, the p-value is 0.01; while for the outcome
483 of hospitalized covid vs. population in all population without UKBB, the p-value is 0.98. We
484 consider this phenomenon directly relating to the corresponding HGI GWAS summary results and
485 further investigations are needed to explain the intrinsic biological reasons.

Declaration of Interests

The authors declare no competing interests.

Author contribution

F.C. and X.J. conceived the study, designed the research program and managed the project.

F.Z., Y.J., Z.L., L.T., N.X., D.H., X.Z., R.X., Y.C., and W.L. collected the samples.

Y.L. finished the laboratory processing and data acquisition.

Z.L. and P.L. preprocessed the data and finished the quality control.

H.Z., L.L. and J.Z. performed the statistical analyses.

Y.S., S.L., and X.S. advised on statistical methods.

H.Z, F.Z, L.L., Y.J., Y.L. Z.L. and J.Z. wrote the manuscript.

All authors participated in revising the manuscript.

Acknowledgement

This study was supported by National Natural Science Foundation of China (32000398), Natural Science Foundation of Guangdong Province, China (2017A030306026), Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases (2019B121205005), The Innovative Major Emergency Project Funding against the COVID-19 in Hubei Province (No. 2020FCA041), the Innovative Major Emergency Project Funding against the COVID-19, HUST (No. 2020kfyXGYJ039), Guangdong Provincial Key Laboratory of Genome Read and Write(No. 2017B030301011) and China National GeneBank.

Reference.

- 1 Jordan, R. E., Adab, P. & Cheng, K. K. Covid-19: risk factors for severe disease and death. *BMJ (Clinical research ed.)* **368**, m1198, doi:10.1136/bmj.m1198 (2020).
- 2 Jin, J. M. *et al.* Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in public health* **8**, 152, doi:10.3389/fpubh.2020.00152 (2020).
- 3 Haitao, T. *et al.* COVID-19 and Sex Differences: Mechanisms and Biomarkers. *Mayo Clinic proceedings* **95**, 2189-2203, doi:10.1016/j.mayocp.2020.07.024 (2020).
- 4 Ejaz, H. *et al.* COVID-19 and comorbidities: Deleterious impact on infected patients. *Journal of infection and public health* **13**, 1833-1839, doi:10.1016/j.jiph.2020.07.014 (2020).
- 5 Wang, F. *et al.* Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. *Cell Discov* **6**, 83, doi:10.1038/s41421-020-00231-4 (2020).
- 6 Ellinghaus, D. *et al.* The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. *medRxiv* (2020).
- 7 Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in COVID-19. *Nature* **591**, 92-98, doi:10.1038/s41586-020-03065-y (2021).
- 8 Shelton, J. F. *et al.* Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. *Nat Genet*, doi:10.1038/s41588-021-00854-7 (2021).
- 9 The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *European journal of human genetics : EJHG* **28**, 715-718, doi:10.1038/s41431-020-0636-6 (2020).
- 10 Ellinghaus, D. *et al.* Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *The New England journal of medicine* **383**, 1522-1534, doi:10.1056/NEJMoa2020283 (2020).
- 11 Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in COVID-19. *Nature* **591**, 92-98, doi:10.1038/s41586-020-03065-y (2021).
- 12 Liu, D. *et al.* Mendelian randomization analysis identified genes pleiotropically associated with the risk and prognosis of COVID-19. *The Journal of infection* **82**, 126-132, doi:10.1016/j.jinf.2020.11.031 (2021).
- 13 Verduijn, M., Siegerink, B., Jager, K. J., Zoccali, C. & Dekker, F. W. Mendelian randomization: use of genetics to enable causal inference in observational studies. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* **25**, 1394-1398, doi:10.1093/ndt/gfq098 (2010).
- 14 Wang, H., Yuan, Z., Pavel, M. A. & Hansen, S. B. The role of high cholesterol in age-related COVID19 lethality. *bioRxiv : the preprint server for biology*, doi:10.1101/2020.05.09.086249 (2020).
- 15 Benlyamani, I., Venet, F., Coudereau, R., Gossez, M. & Monneret, G. Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review. *Cytometry. Part A : the journal of the International Society for Analytical Cytology* **97**, 1217-1221, doi:10.1002/cyto.a.24249 (2020).
- 16 Trouillet-Assant, S. *et al.* Type I IFN immunoprofiling in COVID-19 patients. *The Journal of allergy and clinical immunology* **146**, 206-208.e202, doi:10.1016/j.jaci.2020.04.029 (2020).
- 17 Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S. & Huang, C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral research* **179**, 104811, doi:10.1016/j.antiviral.2020.104811 (2020).
- 18 Lee, J. S. *et al.* Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Science immunology* **5**, doi:10.1126/sciimmunol.abd1554 (2020).

- 19 Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). *Chinese medical journal* **133**, 1087-1095, doi:10.1097/cm9.0000000000000819 (2020).
- 20 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama* **323**, 1239-1242, doi:10.1001/jama.2020.2648 (2020).
- 21 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* **395**, 1054-1062, doi:10.1016/s0140-6736(20)30566-3 (2020).
- 22 Grasselli, G. *et al.* Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA internal medicine* **180**, 1345-1355, doi:10.1001/jamainternmed.2020.3539 (2020).
- 23 Leung, C. Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China. *Mechanisms of ageing and development* **188**, 111255, doi:10.1016/j.mad.2020.111255 (2020).
- 24 Wang, B., Li, R., Lu, Z. & Huang, Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Ageing* **12**, 6049-6057, doi:10.18632/aging.103000 (2020).
- 25 Yin, L. *et al.* rMVP: A Memory-efficient, Visualization-enhanced, and Parallel-accelerated tool for Genome-Wide Association Study. *Genomics, proteomics & bioinformatics*, doi:10.1016/j.gpb.2020.10.007 (2021).
- 26 Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat Genet* **50**, 390-400, doi:10.1038/s41588-018-0047-6 (2018).
- 27 Zou, A. *et al.* Genetic analysis of a novel missense mutation (Gly542Ser) with factor XII deficiency in a Chinese patient of consanguineous marriage. *International journal of hematology* **107**, 436-441, doi:10.1007/s12185-017-2393-z (2018).
- 28 Mack, S. *et al.* A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. *J Lipid Res* **58**, 1834-1844, doi:10.1194/jlr.M076232 (2017).
- 29 McLean, J. W. *et al.* cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature* **330**, 132-137, doi:10.1038/330132a0 (1987).
- 30 Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* **182**, 1214-1231.e1211, doi:10.1016/j.cell.2020.08.008 (2020).
- 31 Wald, A. The fitting of straight lines if both variables are subject to error. *Annals of Mathematical Statistics* **11**, 284-300, doi:10.1214/aoms/1177731868 (1940).
- 32 Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic epidemiology* **37**, 658-665, doi:10.1002/gepi.21758 (2013).
- 33 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology* **44**, 512-525, doi:10.1093/ije/dyv080 (2015).
- 34 Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* **50**, 693-698, doi:10.1038/s41588-018-0099-7 (2018).
- 35 Shin, S. Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet* **46**, 543-550, doi:10.1038/ng.2982 (2014).
- 36 Pan-UKB-team. *Pan UK Biobank*, <<https://pan.ukbb.broadinstitute.org>> (2020).
- 37 Marais, A. D. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. *Pathology* **51**, 165-176, doi:10.1016/j.pathol.2018.11.002 (2019).

- 38 Dallongeville, J., Lussier-Cacan, S. & Davignon, J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. *J Lipid Res* **33**, 447-454 (1992).
- 39 Kuo, C. L. *et al.* APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. *The journals of gerontology. Series A, Biological sciences and medical sciences* **75**, 2231-2232, doi:10.1093/gerona/glaa131 (2020).
- 40 Goldstein, M. R., Poland, G. A. & Graeber, A. C. W. Does apolipoprotein E genotype predict COVID-19 severity? *QJM : monthly journal of the Association of Physicians* **113**, 529-530, doi:10.1093/qjmed/hcaa142 (2020).
- 41 Gkouskou, K. *et al.* COVID-19 enters the expanding network of apolipoprotein E4-related pathologies. *Redox biology* **41**, 101938, doi:10.1016/j.redox.2021.101938 (2021).
- 42 Wei, X. *et al.* Hypolipidemia is associated with the severity of COVID-19. *J Clin Lipidol* **14**, 297-304, doi:10.1016/j.jacl.2020.04.008 (2020).
- 43 Chen, M. H. *et al.* Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell* **182**, 1198-1213.e1114, doi:10.1016/j.cell.2020.06.045 (2020).
- 44 Paces, J., Strizova, Z., Smrz, D. & Cerny, J. COVID-19 and the immune system. *Physiological research* **69**, 379-388, doi:10.33549/physiolres.934492 (2020).
- 45 Zheng, M. *et al.* Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cellular & molecular immunology* **17**, 533-535, doi:10.1038/s41423-020-0402-2 (2020).
- 46 Mishra, A. & Macgregor, S. VEGAS2: Software for More Flexible Gene-Based Testing. *Twin research and human genetics : the official journal of the International Society for Twin Studies* **18**, 86-91, doi:10.1017/thg.2014.79 (2015).
- 47 Reimand, J., Kull, M., Peterson, H., Hansen, J. & Vilo, J. g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments. *Nucleic acids research* **35**, W193-200, doi:10.1093/nar/gkm226 (2007).
- 48 Lin, F. & Shen, K. Type I interferon: From innate response to treatment for COVID-19. *Pediatric investigation* **4**, 275-280, doi:10.1002/ped4.12226 (2020).
- 49 Acharya, D., Liu, G. & Gack, M. U. Dysregulation of type I interferon responses in COVID-19. *Nature reviews. Immunology* **20**, 397-398, doi:10.1038/s41577-020-0346-x (2020).
- 50 Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics (Oxford, England)* **26**, 2867-2873, doi:10.1093/bioinformatics/btq559 (2010).
- 51 Browning, S. R. & Browning, B. L. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. *Am J Hum Genet* **81**, 1084-1097, doi:10.1086/521987 (2007).
- 52 Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7, doi:10.1186/s13742-015-0047-8 (2015).
- 53 Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* **38**, 904-909, doi:10.1038/ng1847 (2006).
- 54 Patterson, N., Price, A. L. & Reich, D. Population structure and eigenanalysis. *PLoS Genet* **2**, e190, doi:10.1371/journal.pgen.0020190 (2006).
- 55 Hemani, G. *et al.* The MR-BASE platform supports systematic causal inference across the human phenome. *eLife* **7**, doi:10.7554/eLife.34408 (2018).
- 56 Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS Genet* **13**, e1007081, doi:10.1371/journal.pgen.1007081 (2017).
- 57 Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. *The Annals of Statistics* **29**, doi:10.1214/aos/1013699998 (2001).
- 58 Ashburner, M. *et al.* Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* **25**, 25-29, doi:10.1038/75556 (2000).

- 59 Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research* **28**, 27-30, doi:10.1093/nar/28.1.27 (2000).
- 60 Joshi-Tope, G. *et al.* Reactome: a knowledgebase of biological pathways. *Nucleic acids research* **33**, D428-432, doi:10.1093/nar/gki072 (2005).
- 61 Pico, A. R. *et al.* WikiPathways: pathway editing for the people. *PLoS biology* **6**, e184, doi:10.1371/journal.pbio.0060184 (2008).
- 62 Guo, X. *et al.* CNSA: a data repository for archiving omics data. *Database : the journal of biological databases and curation* **2020**, doi:10.1093/database/baaa055 (2020).
- 63 Chen, F. Z. *et al.* CNGBdb: China National GeneBank DataBase. *Yi chuan = Hereditas* **42**, 799-809, doi:10.16288/j.ycz.20-080 (2020).

Table 1. Overview of the tested laboratory assessments

Category	Trait	Abbreviation	N
Hematological	Red blood cell count	RBC	420
	Red blood cell distribution width	RDW	420
	White blood cell count	WBC	420
	Lymphocyte count	Lym	420
	Lymphocyte percentage	Lym%	420
	Neutrophil count	Neu	420
	Neutrophil percentage	Neu%	420
	Eosinophil count	Eos	420
	Eosinophil percentage	Eos%	420
	Basophil count	Bas	420
	Basophil percentage	Bas%	420
	Monocyte count	Mon	420
	Monocyte percentage	Mon%	420
	Platelet count	Plt	420
	Platelet distribution width	PDW	420
	Mean platelet volume	MPV	420
	Hematocrit	Hct	420
	Plateletcrit	PCT	420
	Hemoglobin	Hb	420
	Mean corpuscular hemoglobin	MCH	420
Mean corpuscular hemoglobin concentration	MCHC	420	
Mean corpuscular volume	MCV	420	
Anticoagulation	Activated partial thromboplastin time	APTT	410
	D-dimer	D-dimer	410
	Erythrocyte sedimentation rate	ESR	184
	Fibrinogen	FIB	410
	International normalized ratio	INR	410
	Prothrombin time	PT	410
	Thrombin time	TT	410
Electrolyte	Sodium	Na	420
	Potassium	K	420
	Calcium	Ca	420
	Magnesium	Mg	420
	Chloride	Cl	420
	Phosphorus	P	420
Lipid	Anion gap	AG	420
	Triglyceride	TG	406
	Apoprotein A	apoA	402
	Apoprotein B	apoB	402
	Lipoprotein(a)	LpA	402
	Total cholesterol	TC	406
	High-density-lipoprotein cholesterol	HDL-C	406
Low-density-lipoprotein cholesterol	LDL-C	406	
Protein	Total protein	TP	420
	Albumin	Alb	420
	Globulin	Glb	420
	Albumin/globulin ratio	A/G	420
Liver-related	Aspartate aminotransferase	AST	420
	Alanine aminotransferase	ALT	420
	Aspartate aminotransferase/alanine aminotransferase ratio	AST/ALT	420
	Total bilirubin	Tbil	420
	Direct bilirubin	Dbil	420
	Indirect bilirubin	Ibil	420
	Acetyl cholinesterase	AChE	350
	Alkaline phosphatase	AKP	420
	Lactate dehydrogenase	LDH	420
	γ -glutamyl transferase	GGT	420
Prealbumin	PA	420	
Kidney-related	Total bile acids	TBA	420
	Blood urea nitrogen	BUN	420
	Serum creatinine	Cre	420
	Uric acid	UA	420
Heart-related	α -hydroxybutyric dehydrogenase	HBDH	414
	Myoglobin	Mb	343
	High-sensitivity cardiac troponin	hscTn	347
	Homocysteine	Hcy	350
	Brain natriuretic peptide	BNP	309
	Creatine kinase	CK	414
	Creatine kinase-MB active	CK-MBa	414
Creatine kinase-MB quality	CK-MBq	343	
Inflammation	C-reactive protein	CRP	418
	Interleukin-6	IL6	351
	Procalcitonin	PCTN	394
Other biochemical	Cystatin C	CysC	420
	Osmotic pressure	Osm	420
	Ferritin	FER	203
	Blood glucose	BG	420
	Total carbon dioxide	TCO2	420

Table 2. The concrete associations identified from single-variant GWAS analysis

Trait	SNP	CHR	POS	REF	ALT	Mapped/Closest Gene	AF	R2	beta	se	p-value	N	European	Asian	Chinese
APTT	rs1801020	5	177409531	A	G	<i>F12</i>	0.254	1.000	-0.606	0.071	4.13E-16	410	X	√	X
LpA	rs56393506	6	160668275	C	T	<i>LPA</i>	0.114	0.998	0.817	0.103	1.97E-14	402	√	X	X
Tbil	rs28946889	2	233762816	G	T	<i>UGT1A</i> Complex	0.400	0.996	-0.521	0.067	5.08E-14	420	X	√	X
Ibil	rs28946889	2	233762816	G	T	<i>UGT1A</i> Complex	0.400	0.996	-0.585	0.068	1.51E-16	420	X	√	X
apoA	rs11032789	11	34624907	T	G	<i>EHF</i>	0.040	1.000	0.960	0.151	6.40E-10	402	X	X	X
LDL-C	rs7412	19	44908822	C	T	<i>ApoE</i>	0.092	0.998	-0.652	0.114	2.30E-08	406	√	√	√
WBC	rs9268517	6	32411963	C	T	<i>BTNL2, HLA-DRA</i>	0.067	1.000	0.721	0.129	4.05E-08	420	X	X	X


Notes. AF indicates the allele frequency for the effect/alternate allele; R2 indicates the imputation score based on EAS population from the 1000 Genome Project; N is the sample size used in GWAS analysis; “√” and “X” indicate the corresponding associations were previously reported and not reported in a population based on genomic studies, respectively.

Table 3. The summary of eight reported COVID-19 illness associated loci

SNP	Chr:BP	Locus	p-value	A1	1KGP Asian Freq	1KGP European Freq	A1 Freq	Mild Freq	Severe Freq
rs73064425	3:45901089	LZTFL1	/	T	0.005	0.0795	0.005365	0.005882	0.005068
rs9380142	6:29798794	HLA-G	0.846804	G	0.3492	0.3439	0.43133	0.4206	0.4375
rs143334143	6:31121426	CCHCR1	0.966751	A	0.0347	0.1123	0.059013	0.06176	0.05743
rs3131294	6:32180146	NOTCH4	/	A	0.0079	0.1133	0.006438	0.008824	0.005068
rs10735079	12:113380008	OAS1-OAS3	0.433044	G	0.252	0.3638	0.233906	0.2265	0.2382
rs2109069	19:4719443	DPP9	0.788196	A	0.1399	0.3211	0.143777	0.1382	0.147
rs74956615	19:10427721	TYK2	/	/	/	/	/	/	/
rs2236757	21:34624917	IFNAR2	0.4025	G	0.4345	0.7058	0.381974	0.3618	0.3936

Notes. A1 denotes the effect/alternate allele. 1KGP Asian Freq indicates the allele frequency in Asian population from the 1000 Genome Project. Mild Freq indicates the allele frequency in patients from mild and moderate (grouped into mild) groups.

Figure 1. Basic clinical information of COVID-19 patients



Notes. (A) Pie diagrams for sex ratio and age distribution of 466 samples. (B) Bar charts for severity category and histogram of hospitalized days. In severity chart, the blue and green bars indicate the mild group, orange and red bars indicate the severe group. (C) Bar chart for the counts of severity in each age range. (D) Bar charts for the distributions of comorbidities and symptoms. For the comorbidities, HTN, CHD, BRN, TUM, SMK, CHB, COPD, HBV, ASM, TUB, and CKD indicate hypertension, coronary heart disease, brain infarction, tumor, smoking history, chronic bronchitis, chronic obstructive pulmonary disease, Hepatitis B virus, asthma, tuberculosis, and chronic kidney disease, respectively. For the symptoms, COU, FTG, CHT, APP, SPU, MUS, DIA, VOM, HDC, DIZ, THR, DYS, PAL, RHI, NEW, CHP, HEMO, ABD, and HEMO indicate cough, fatigue, chest tightness, poor appetite, sputum, muscle ache, diarrhea, vomiting, headache, dizziness, sore throat, dyspnea, palpitation, rhinorrhea, night sweating, chest pain, hemoptysis, abdominal pain, and hematemesis, respectively.

Figure 2. The workflow of the main analyses performed in this study






Figure 3. The Manhattan plots and QQ-plots of three strong signals




Notes. Figures A, C, and E are Manhattan plots and Figures B, D, F are QQ-plots for APTT, LpA, and Ibil, respectively.

Figure 4. The genetic mechanisms of *ApoE* influencing severity by acting on cholesterol levels




Notes. (A) Manhattan plot of the GWAS single-variant test results of LDL-C. The red dash line indicates the genome-wide significance threshold $5E-8$. (B) The fitted line of SNP effects on severity status versus SNP effects on LDL-C with 11 SNPs significantly associated with LDL-C in BBJ database. (C) Forest plot for MR effect sizes of LDL-C on severity status based on BBJ database. (D) A genetic mechanism of how *ApoE* genotype influences the susceptibility and severity of COVID-19 disease.

Figure 5. The genetic mechanisms of *MHC* system determining severity by controlling WBC counts




Notes. (A) Manhattan plot of the GWAS single-variant test results of WBC counts. The red dash line indicates the genome-wide significance threshold $5E-8$. (B) The fitted line of SNP effects on severity status versus SNP effects on WBC counts with 48 SNPs significantly associated with WBC counts in database with 151,807 East Asian participants. (C) Forest plot for MR effect sizes of WBC counts on severity status. (D) A genetic mechanism of how *MHC* system genotype influences the severity of COVID-19.

Figure 6. The time-series laboratory features



Notes. The top three figures show variation trends of apoA, LDL-C, and WBC counts over time. The pink, light blue, and orange lines indicate the patients are grouped into mild, recovery, and death team, respectively. The y-axis denotes the quantities of each trait. The bottom three figures show regression associations between each trait with disease severity (green) and clinical outcome (yellow) over time. The y-axis denotes $-\log_{10}(\text{p-value})$ multiplied by the effect direction (positive effect is 1 and negative effect is -1).

Figure 7. The genome-wide association studies of COVID-19 severity: a case-control study



Notes. (A) Circular-Manhattan plots for clinical traits. The inner circle is for severity status (mild vs. severe), the middle circle is for clinical outcome assessments (survival vs. death), and the outer circle is for disease duration (hospitalized days). (B) The QQ-plot for three clinical traits. (C) Bubble plot of GSEA analysis based on the single-variant and gene-based studies on severity status. The red dashed line is the threshold of 0.05.